# 2026-04938: FDA Asks: Better Drug Trial Paperwork or Same Old Headache?

2026-04938, Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2026-03-13, effective 2026-05-12; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-04938
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-04938
- Title: Agency Information Collection Activities; Proposed Collection; Comment Request; Investigational New Drug Application Requirements
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 91 FR 12422
- Published: 2026-03-13
- Effective: 2026-05-12
- Comments close: 2026-05-12
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

FDA Asks: Better Drug Trial Paperwork or Same Old Headache?

## Summary

The FDA wants your thoughts on how it collects info about new drug tests before they’re approved. This affects drug companies and researchers who submit applications to test new medicines. You’ve got until May 12, 2026, to share your comments, helping shape smoother, clearer rules without extra costs or delays.

## Abstract

The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on information collection associated with investigational new drugs and investigational new drug applications.

## Effects PRIA read

- Large IND Reporting Burden: cost, high. If you sponsor or run clinical drug trials, you must follow 21 CFR part 312 reporting and recordkeeping rules that FDA estimates generate millions of hours of annual burden: for human drugs FDA lists 152,856 total responses and 23,016,423 total annual hours, and for biologics FDA lists 48,179 total…
- New RWE/RWD Tracking Fields: cost, medium. Form FDA 1571 was updated to add tracking fields for real-world evidence and real-world data (RWE/RWD) under the PDUFA VII commitments so sponsors submitting RWE/RWD will provide those new data elements.
- Electronic Submission Requirement: cost, low. FDA requires that the information for INDs be submitted electronically (forms are available electronically; printed forms can be requested and fees may apply), so sponsors and investigators must use electronic submission channels for IND-related forms.
- Form 1571 Web Interface Available: benefit, low. FDA offers a new web-based interface for completing and electronically submitting Form FDA 1571 from mobile devices or desktops, which lets sponsors (including sponsor-investigators) fill out and submit IND applications online.
- Right to Try Annual Report Deadline: cost, low. Sponsors and manufacturers who provide an "eligible investigational drug" under the Right to Try Act must submit an annual report using Form FDA 5023 no later than March 31 each year, covering data for the preceding calendar year.

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2026-04938 on federalregister.gov](https://www.federalregister.gov/documents/2026/03/13/2026-04938/agency-information-collection-activities-proposed-collection-comment-request-investigational-new)
- [2026-04938 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-03-13/pdf/2026-04938.pdf)

## Related
- [Previous: 2026-04937, New Postal Products](https://policyrisk.com/federal-register/2026-04937)
- [Next: 2026-04939, Agency Information Collection Activities; Submission for Office of Management a…](https://policyrisk.com/federal-register/2026-04939)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-04938 (as of 2026-06-08).
